Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I randomized, double-blind, placebo-controlled clinical study assessing safety profile of Lipisense, as well as its pharmacokinetic properties and pharmacodynamic effects for the treatment of severe hypertriglyceridemia as well as the rare disease Familial Chylomicronemia Syndrome (FCS)

Next Previous
Search
Trial Profile

A phase I randomized, double-blind, placebo-controlled clinical study assessing safety profile of Lipisense, as well as its pharmacokinetic properties and pharmacodynamic effects for the treatment of severe hypertriglyceridemia as well as the rare disease Familial Chylomicronemia Syndrome (FCS)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 06 Nov 2024 According to Secarna Pharmaceuticals media release, company estimates that the study is expected to be fully recruited during the first half of 2025.
  • 01 Jul 2022 New trial record
  • 31 May 2022 According to Secarna Pharmaceuticals media release, Lipigon received approval from the Swedish Medical Products Agency last week to commence this phase I clinical study, first subject has been dosed in this trial

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top